B-cell and T-cell epitopes in anti-factor VIII immune responses

Clinical Reviews in Allergy and Immunology

Volumn 37, Issue 2, 2009, Pages 80-95

  Pratt, Kathleen P ^a,b   Thompson, Arthur R ^a,b  

^a PUGET SOUND BLOOD CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

B cell epitopes; Hemophilia A; Inhibitory antibody; T cell immune responses

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; EPITOPE; PROCOAGULANT; RECOMBINANT BLOOD CLOTTING FACTOR 8; T LYMPHOCYTE RECEPTOR;

AMINO ACID SEQUENCE; ANTIGEN PRESENTING CELL; ANTIGENICITY; B LYMPHOCYTE; GENE MUTATION; HEMOPHILIA A; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; REVIEW; T LYMPHOCYTE;

AUTOANTIBODIES; B-LYMPHOCYTES; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MODELS, MOLECULAR; T-LYMPHOCYTES;

EID: 70349258234     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12016-009-8120-7     Document Type: Review

References (177)

1. AR Thompson 2003 Structure and function of the factor VIII gene and protein Semin Thromb Hemost 29 11 22 12640560
2. G van Dieijen G Tans J Rosing HC Hemker 1981 The role of phospholipid and factor VIIIa in the activation of bovine factor X J Biol Chem 256 3433 3442 6782101
3. J Gitschier WI Wood TM Goralka KL Wion EY Chen DH Eaton GA Vehar DJ Capon RM Lawn 1984 Characterization of the human factor VIII gene Nature 312 326 330 6438525
4. JJ Toole JL Knopf JM Wozney LA Sultzman JL Buecker DD Pittman RJ Kaufman E Brown C Shoemaker EC Orr, et al. 1984 Molecular cloning of a cDNA encoding human antihaemophilic factor Nature 312 342 347 6438528
5. GA Vehar B Keyt D Eaton H Rodriguez DP O'Brien F Rotblat H Oppermann R Keck WI Wood RN Harkins, et al. 1984 Structure of human factor VIII Nature 312 337 342 6438527
6. PJ Lenting JA van Mourik K Mertens 1998 The life cycle of coagulation factor VIII in view of its structure and function Blood 92 3983 3996 9834200
7. RJ Kaufman SW Pipe L Tagliavacca M Swaroop M Moussalli 1997 Biosynthesis, assembly and secretion of coagulation factor VIII Blood Coagul Fibrinolysis 8 Suppl 2 S3 S14 9607108
8. PJ Fay TM Smudzin FJ Walker 1991 Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity J Biol Chem 266 20139 20145 1939075
9. S Ehrenforth W Kreuz I Scharrer R Linde M Funk T Gungor B Krackhardt B Kornhuber 1992 Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs Lancet 339 594 598 1347102
10. JM Lusher S Arkin CF Abildgaard RS Schwartz 1993 Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group N Engl J Med 328 453 459 8421474
11. GL Bray ED Gomperts S Courter R Gruppo EM Gordon M Manco-Johnson A Shapiro E Scheibel G White 3rd M Lee 1994 A multicenter study of recombinant factor VIII (recombinate),: safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group Blood 83 2428 2435 8167332
12. W Kreuz CE Ettingshausen A Zyschka J Oldenburg IM Saguer S Ehrenforth T Klingebiel 2002 Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products Semin Thromb Hemost 28 285 290 12098090
13. JM Lusher CA Lee CM Kessler CL Bedrosian 2003 The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A Haemophilia 9 38 49 12558777
14. JC Ngo M Huang DA Roth BC Furie B Furie 2008 Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex Structure 16 597 606 18400180
15. BW Shen PC Spiegel CH Chang JW Huh JS Lee J Kim YH Kim BL Stoddard 2008 The tertiary structure and domain organization of coagulation factor VIII Blood 111 1240 1247 17965321
16. G Kemball-Cook EG Tuddenham AI Wacey 1998 The factor VIII structure and mutation resource site: HAMSTeRS version 5 Nucleic Acids Res 26 216 219 9399839
17. Kemball-Cook, G. Hamsters: The Haemophilia A Mutation, Structure, Test and Resource Site http://europium.csc.mrc.ac.uk
18. PH Byers 2002 Killing the messenger: new insights into nonsense-mediated mRNA decay J Clin Invest 109 3 6 11781342
19. D David IM Santos K Johnson EG Tuddenham JH McVey 2003 Analysis of the consequences of premature termination codons within factor VIII coding sequences J Thromb Haemost 1 139 146 12871551
20. JA Naylor PM Green CR Rizza F Giannelli 1993 Analysis of factor VIII mRNA reveals defects in everyone of 28 haemophilia A patients Hum Mol Genet 2 11 17 8490618
21. D Lakich HH Kazazian Jr SE Antonarakis J Gitschier 1993 Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A Nat Genet 5 236 241 8275087
22. J Oldenburg O El-Maarri R Schwaab 2002 Inhibitor development in correlation to factor VIII genotypes Haemophilia 8 Suppl 2 23 29 11966849
23. AR Thompson ME Murphy M Liu EL Saenko JF Healey P Lollar D Scandella 1997 Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation Blood 90 1902 1910 9292523
24. K Fijnvandraat EAM Turenhout EN van den Brink JW ten Cate JA van Mourik M Peters J Voorberg 1997 The missense mutation Arg593-Cys is related to antibody formation in a patient with mild hemophilia A Blood 89 4371 4377 9192760
25. CR Hay 1998 Factor VIII inhibitors in mild and moderate-severity haemophilia A Haemophilia 4 558 563 9873794
26. K Peerlinck MG Jacquemin J Arnout MF Hoylaerts JG Gilles R Lavend'homme KM Johnson K Freson D Scandella JM Saint-Remy J Vermylen 1999 Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A Blood 93 2267 2273 10090936
27. M Jacquemin V Vantomme C Buhot R Lavend'homme W Burny N Demotte P Chaux K Peerlinck J Vermylen B Maillere P van der Bruggen JM Saint-Remy 2003 CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A Blood 101 1351 1358 12393451
28. A Sharathkumar D Lillicrap VS Blanchette M Kern J Leggo AM Stain L Brooker MD Carcao 2003 Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A J Thromb Haemost 1 1228 1236 12871324
29. GC White 2nd CL Kempton A Grimsley B Nielsen HR Roberts 2005 Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs J Thromb Haemost 3 1676 1681 16102033
30. K Peerlinck M Jacquemin 2006 Characteristics of inhibitors in mild/moderate haemophilia A Haemophilia 12 Suppl 6 43 47 17123393
31. J Oldenburg A Pavlova 2006 Genetic risk factors for inhibitors to factors VIII and IX Haemophilia 12 Suppl 6 15 22 17123389
32. Mannucci PM, Glangrande PLF (1994) Acquired disorders of coagulation, 3rd edn. Churchill Livingstone, London
33. R Prescott H Nakai EL Saenko I Scharrer IM Nilsson JE Humphries D Hurst G Bray D Scandella 1997 The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups Blood 89 3663 3671 9160671
34. G Allen L Aledort 2006 Therapeutic decision-making in inhibitor patients Am J Hematol 81 71 72 16369965
35. LM Aledort 1999 Economic aspects of haemophilia care Haemophilia 5 373 10583521
36. RL Bohn LM Aledort KG Putnam BM Ewenstein H Mogun J Avorn 2004 The economic impact of factor VIII inhibitors in patients with haemophilia Haemophilia 10 63 68 14962222
37. DH Scandella H Nakai M Felch W Mondorf I Scharrer LW Hoyer EL Saenko 2001 In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic Thromb Res 101 377 385 11297754
38. D Scandella S DeGraaf Mahoney M Mattingly D Roeder L Timmons CA Fulcher 1988 Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli Proc Natl Acad Sci USA 85 6152 6156 2457907
39. CA Fulcher S de Graaf Mahoney JR Roberts CK Kasper TS Zimmerman 1985 Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments Proc Natl Acad Sci USA 82 7728 7732 2415970
40. D Scandella M Mattingly S de Graaf CA Fulcher 1989 Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization Blood 74 1618 1626 2477082
41. D Scandella M Mattingly R Prescott 1993 A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2 Blood 82 1767 1775 7691236
42. JG Gilles J Arnout J Vermylen JM Saint-Remy 1993 Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction Blood 82 2452 2461 7691260
43. MA Sahud KP Pratt O Zhukov K Qu AR Thompson 2007 ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay Haemophilia 13 317 322 17498082
44. M Ling EM Duncan SE Rodgers AM Street JV Lloyd 2003 Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay J Thromb Haemost 1 2548 2553 14675091
45. CK Kasper L Aledort D Aronson R Counts JR Edson J van Eys J Fratantoni D Green J Hampton M Hilgartner P Levine J Lazerson C McMillan J Penner S Shapiro NR Shulman 1975 Proceedings: A more uniform measurement of factor VIII inhibitors Thromb Diath Haemorrh 34 612 1198543
46. B Verbruggen I Novakova H Wessels J Boezeman M van den Berg E Mauser-Bunschoten 1995 The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability Thromb Haemost 73 247 251 7792738
47. S Lacroix-Desmazes MD Kazatchkine SV Kaveri 2003 Catalytic antibodies to factor VIII in haemophilia A Blood Coagul Fibrinolysis 14 Suppl 1 S31 S34 14567533
48. S Lacroix-Desmazes A Moreau Sooryanarayana C Bonnemain N Stieltjes A Pashov Y Sultan J Hoebeke MD Kazatchkine SV Kaveri 1999 Catalytic activity of antibodies against factor VIII in patients with hemophilia A Nat Med 5 1044 1047 10470082
49. S Lacroix-Desmazes J Bayry N Misra MP Horn S Villard A Pashov N Stieltjes R d'Oiron JM Saint-Remy J Hoebeke MD Kazatchkine J Reinbolt D Mohanty SV Kaveri 2002 The prevalence of proteolytic antibodies against factor VIII in hemophilia A N Engl J Med 346 662 667 11870243
50. B Wootla S Dasgupta JD Dimitrov J Bayry H Levesque JY Borg A Borel-Derlon DN Rao A Friboulet SV Kaveri S Lacroix-Desmazes 2008 Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia J Immunol 180 7714 7720 18490775
51. S Lacroix-Desmazes A Moreau A Pashov Sooryanarayana D Stahl JM Saint-Remy SV Kaveri MD Kazatchkine 2000 Natural antibodies to factor VIII Semin Thromb Hemost 26 157 165 10919408
52. S Lacroix-Desmazes AM Navarrete S Andre J Bayry SV Kaveri S Dasgupta 2008 Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A Blood 112 240 249 18469198
53. CE Ettingshausen W Kreuz 2006 Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development Haemophilia 12 Suppl 6 102 106 17123402
54. P Lollar ET Parker JE Curtis SL Helgerson LW Hoyer ME Scott D Scandella 1994 Inhibition of human factor VIIIa by anti-A2 subunit antibodies J Clin Invest 93 2497 2504 8200986
55. RT Barrow P Lollar 2006 Neutralization of anti-factor VIII inhibitors by recombinant porcine factor VIII J Thromb Haemost 4 10 2223 2229 16856973
56. PB Kernoff 1984 Porcine factor VIII: preparation and use in treatment of inhibitor patients Prog Clin Biol Res 150 207 224 6431429
57. JF Healey IM Lubin H Nakai EL Saenko LW Hoyer D Scandella P Lollar 1995 Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII J Biol Chem 270 14505 14509 7540171
58. IM Lubin JF Healey RT Barrow D Scandella P Lollar 1997 Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis J Biol Chem 272 30191 30195 9374501
59. C Ansong SM Miles PJ Fay 2006 Epitope mapping factor VIII A2 domain by affinity-directed mass spectrometry: residues 497-510 and 584-593 comprise a discontinuous epitope for the monoclonal antibody R8B12 J Thromb Haemost 4 842 847 16634755
60. PA Foster CA Fulcher RA Houghten S de Graaf Mahoney TS Zimmerman 1988 Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain J Clin Invest 82 123 128 2839543
61. I Kuwabara H Maruyama S Kamisue M Shima A Yoshioka IN Maruyama 1999 Mapping of the minimal domain encoding a conformational epitope by lambda phage surface display: factor VIII inhibitor antibodies from haemophilia A patients J Immunol Methods 224 89 99 10357210
62. M Arai D Scandella LW Hoyer 1989 Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid J Clin Invest 83 1978 1984 2498393
63. JF Healey RT Barrow HM Tamim IM Lubin M Shima D Scandella P Lollar 1998 Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII Blood 92 3701 3709 9808564
64. M Shima D Scandella A Yoshioka H Nakai I Tanaka S Kamisue S Terada H Fukui 1993 A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine Thromb Haemost 69 240 246 7682339
65. PA Foster CA Fulcher RA Houghten TS Zimmerman 1990 A synthetic factor VIII peptide of eight amino acid residues (1677-1684) contains the binding region of an anti-factor VIII antibody which inhibits the binding of factor VIII to von Willebrand factor Thromb Haemost 63 403 406 2119526
66. D Scandella GE Gilbert M Shima H Nakai C Eagleson M Felch R Prescott KJ Rajalakshmi LW Hoyer E Saenko 1995 Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site Blood 86 1811 1819 7544643
67. RT Barrow JF Healey MG Jacquemin JM Saint-Remy P Lollar 2001 Antigenicity of putative phospholipid membrane-binding residues in factor VIII Blood 97 169 174 11133757
68. EL Saenko M Shima KJ Rajalakshmi D Scandella 1994 A role for the C2 domain of factor VIII in binding to von Willebrand factor J Biol Chem 269 11601 11605 7512568
69. M Shima A Yoshioka H Nakai I Tanaka Y Sawamoto S Kamisue S Terada H Fukui 1991 Epitope localization of monoclonal antibodies against factor VIII light chain which inhibit complex formation by factor VIII with von Willebrand factor Int J Hematol 54 515 522 1724391
70. EL Saenko D Scandella 1995 A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor J Biol Chem 270 13826 13833 7775440
71. A Lajmanovich G Hudry-Clergeon JM Freyssinet G Marguerie 1981 Human factor VIII procoagulant activity and phospholipid interaction Biochim Biophys Acta 678 132 136 6796129
72. LO Andersson JE Brown 1981 Interaction of factor VIII-von Willebrand Factor with phospholipid vesicles Biochem J 200 161 167 6800356
73. R d'Oiron JM Lavergne R Lavend'homme A Benhida JC Bordet C Negrier K Peerlinck J Vermylen JM Saint-Remy M Jacquemin 2004 Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development Blood 103 155 157 12969981
74. EA James WW Kwok RA Ettinger AR Thompson KP Pratt 2007 T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide J Thromb Haemost 5 2399 2407 18034765
75. KP Pratt BW Shen K Takeshima EW Davie K Fujikawa BL Stoddard 1999 Structure of the C2 domain of human factor VIII at 1.5 A resolution Nature 402 439 442 10586887
76. DA Lewis KD Moore TL Ortel 2003 Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid binding Blood Coagul Fibrinolysis 14 361 368 12945878
77. EL Saenko M Shima GE Gilbert D Scandella 1996 Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition J Biol Chem 271 27424 27431 8910322
78. SL Meeks JF Healey ET Parker RT Barrow P Lollar 2007 Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation Blood 110 4234 4242 17848617
79. T Albert C Egler S Jakuschev U Schuldenzucker A Schmitt O Brokemper M Zabe-Kuhn D Hoffmann J Oldenburg R Schwaab 2008 The B-cell epitope of the monoclonal anti-factor VIII antibody ESH8 characterized by peptide array analysis Thromb Haemost 99 634 637 18327416
80. K Nogami M Shima H Nakai I Tanaka H Suzuki S Morichika M Shibata EL Saenko D Scandella JC Giddings A Yoshioka 1999 Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect Br J Haematol 107 196 203 10520041
81. E Saenko A Sarafanov N Greco M Shima K Loster H Schwinn D Josic 1999 Use of surface plasmon resonance for studies of protein-protein and protein-phospholipid membrane interactions. Application to the binding of factor VIII to von Willebrand factor and to phosphatidylserine-containing membranes J Chromatogr A 852 59 71 10480230
82. S Raut M Di Giambattista SA Bevan AR Hubbard TW Barrowcliffe R Laub 1998 Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation Thromb Haemost 80 624 631 9798982
83. Y Sawamoto R Prescott D Zhong EL Saenko E Mauser-Bunschoten K Peerlinck M van den Berg D Scandella 1998 Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors Thromb Haemost 79 62 68 9459325
84. K Nogami M Shima K Hosokawa M Nagata T Koide EL Saenko I Tanaka M Shibata A Yoshioka 2000 Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689 J Biol Chem 275 25774 25780 10831589 (Pubitemid 30687082)
85. K Nogami M Shima K Hosokawa T Suzuki T Koide EL Saenko D Scandella M Shibata S Kamisue I Tanaka A Yoshioka 1999 Role of factor VIII C2 domain in factor VIII binding to factor Xa J Biol Chem 274 31000 31007 10521497
86. K Nogami M Shima K Nishiya Y Sakurai I Tanaka JC Giddings EL Saenko A Yoshioka 2002 Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: a new anti-factor VIII inhibitory mechanism Thromb Haemost 87 459 465 11916079
87. SL Meeks JF Healey ET Parker RT Barrow P Lollar 2008 Non-classical anti-C2 domain antibodies are present in patients with factor VIII inhibitors Blood 112 4 1151 1153 18495957
88. MG Jacquemin BG Desqueper A Benhida L Vander Elst MF Hoylaerts M Bakkus K Thielemans J Arnout K Peerlinck JG Gilles J Vermylen JM Saint-Remy 1998 Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor Blood 92 496 506 9657749
89. PC Spiegel Jr M Jacquemin JM Saint-Remy BL Stoddard KP Pratt 2001 Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII Blood 98 13 19 11418455
90. JG Gilles SC Grailly M De Maeyer MG Jacquemin LP VanderElst JM Saint-Remy 2004 In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody Blood 103 2617 2623 14670927
91. D Zhong EL Saenko M Shima M Felch D Scandella 1998 Some human inhibitor antibodies interfere with factor VIII binding to factor IX Blood 92 136 142 9639509
92. PJ Lenting JW van de Loo MJ Donath JA van Mourik K Mertens 1996 The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX J Biol Chem 271 1935 1940 8567641
93. K Fijnvandraat PH Celie EA Turenhout JW ten Cate JA van Mourik K Mertens M Peters J Voorberg 1998 A human alloantibody interferes with binding of factor IXa to the factor VIII light chain Blood 91 2347 2352 9516133
94. HJ Brinkman K Mertens JA van Mourik 2002 Phospholipid-binding domain of factor VIII is involved in endothelial cell-mediated activation of factor X by factor IXa Arterioscler Thromb Vasc Biol 22 511 516 11884299
95. RT Barrow JF Healey D Gailani D Scandella P Lollar 2000 Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules Blood 95 564 568 10627463
96. M Shima CA Fulcher S de Graaf Mahoney RA Houghten TS Zimmerman 1988 Localization of the binding site for a factor VIII activity neutralizing antibody to amino acid residues Asp1663-Ser1669 J Biol Chem 263 10198 10203 2455712
97. S Raut S Villard S Grailly JG Gilles C Granier JM Saint-Remy TW Barrowcliffe 2003 Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor Thromb Haemost 90 385 397 12958606
98. CC Huang MC Shen JY Chen MH Hung TC Hsu SW Lin 2001 Epitope mapping of factor VIII inhibitor antibodies of Chinese origin Br J Haematol 113 915 924 11442484
99. M Jacquemin A Benhida K Peerlinck B Desqueper L Vander Elst R Lavend'homme R d'Oiron R Schwaab M Bakkus K Thielemans JG Gilles J Vermylen JM Saint-Remy 2000 A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor Blood 95 156 163 10607698
100. JG Gilles R Lavend'homme K Peerlinck MG Jacquemin M Hoylaerts S Jorieux C Mazurier J Vermylen JM Saint-Remy 1999 Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes Thromb Haemost 82 40 45 10456452
101. RJ Hamer JA Koedam NH Beeser-Visser JJ Sixma 1987 The effect of thrombin on the complex between factor VIII and von Willebrand factor Eur J Biochem 167 253 259 3113951
102. DA Lewis N Bovenschen K Mertens J Voorberg TL Ortel 2005 Phospholipid vesicles interfere with the binding of antibody fragments to the light chain of factor VIII Thromb Haemost 93 833 841 15886796
103. A Kallas M Pooga A Benhida M Jacquemin JM Saint-Remy 2002 Epitope specificity of anti-FVIII antibodies during immune tolerance therapy with factor VIII preparation containing von Willebrand factor Thromb Res 107 291 302 12565716
104. S Villard D Piquer S Raut JP Leonetti JM Saint-Remy C Granier 2002 Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8 J Biol Chem 277 27232 27239 12011059
105. S Villard S Lacroix-Desmazes T Kieber-Emmons D Piquer S Grailly A Benhida SV Kaveri JM Saint-Remy C Granier 2003 Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor Blood 102 949 952 12676786
106. DG Chaves C Velloso-Rodrigues V Moreau C Nguyen S Villard AR Belisario C Granier MM Santoro 2008 Reactivity profile of anti-factor VIII antibodies with designed synthetic peptides mimicking epitopes of the C2 and a1 domains Br J Haematol 141 708 715 18422780
107. C Muhle S Schulz-Drost AV Khrenov EL Saenko J Klinge H Schneider 2004 Epitope mapping of polyclonal clotting factor VIII-inhibitory antibodies using phage display Thromb Haemost 91 619 625 14983240
108. M Di Giambattista T Branckaert R Laub 2001 Mapping of natural anti-factor VIII antibodies in plasma pools from healthy donors: use of rationally designed synthetic peptides Biologicals 29 229 232 11851320
109. S Planque MA Escobar KC Smith H Taguchi Y Nishiyama E Donnachie KP Pratt S Paul 2008 Covalent inactivation of factor VIII antibodies from hemophilia A patients by an electrophilic FVIII Analog J Biol Chem 283 11876 11886 18337255
110. CA Lee 2002 The evidence behind inhibitor treatment with porcine factor VIII Pathophysiol Haemost Thromb 32 Suppl 1 5 8 12214138
111. JF Healey IM Lubin P Lollar 1996 The cDNA and derived amino acid sequence of porcine factor VIII Blood 88 4209 4214 8943856
112. CB Doering JF Healey ET Parker RT Barrow P Lollar 2002 High level expression of recombinant porcine coagulation factor VIII J Biol Chem 277 38345 38349 12138172 (Pubitemid 35154689)
113. K Koshihara J Qian P Lollar LW Hoyer 1995 Immunoblot cross-reactivity of factor VIII inhibitors with porcine factor VIII Blood 86 2183 2190 7662967
114. IM Lubin JF Healey D Scandella MS Runge P Lollar 1994 Elimination of a major inhibitor epitope in factor VIII J Biol Chem 269 8639 8641 7510693
115. J Gribble MB Garvey 2000 Porcine factor VIII provides clinical benefit to patients with high levels of inhibitors to human and porcine factor VIII Haemophilia 6 482 485 11012689
116. AS De Groot DW Scott 2007 Immunogenicity of protein therapeutics Trends Immunol 28 482 490 17964218
117. DM Dimichele 2006 Management of factor VIII inhibitors Int J Hematol 83 119 125 16513529
118. G Mariani S Siragusa BL Kroner 2003 Immune tolerance induction in hemophilia A: a review Semin Thromb Hemost 29 69 76 12640568
119. J Astermark 2003 Treatment of the bleeding inhibitor patient Semin Thromb Hemost 29 77 86 12640569
120. Ettinger RA JE, Thompson AR, Kwok WW, Pratt KP (2007) C2 domain T-cell epitopes in hemophilia A subjects with the mutation A2201P. in XXIst Congress of the International Society on Thrombosis and Hemostasis
121. James EA, v. HS, Ettinger RA, Thompson AR, Kwok WW, Voorberg J, Pratt KP (2007), Epitope identification and generation of an antigen-specific T-cell clone in a mild hemophilia A inhibitor subject with missense genotype R593C. abstract 1159, 351a
122. KP Pratt J Qian E Ellaban DK Okita BM Diethelm-Okita B Conti-Fine DW Scott 2004 Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site Thromb Haemost 92 522 528 15351848
123. GL Bray BL Kroner S Arkin LW Aledort MW Hilgartner ME Eyster MV Ragni JJ Goedert 1993 Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study Am J Hematol 42 375 379 8493988
124. EN van den Brink WS Bril EA Turenhout M Zuurveld N Bovenschen M Peters TT Yee K Mertens DA Lewis TL Ortel P Lollar D Scandella J Voorberg 2002 Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII Blood 99 2828 2834 11929772
125. EN van Den Brink EA Turenhout J Davies N Bovenschen K Fijnvandraat WH Ouwehand M Peters J Voorberg 2000 Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes Blood 95 558 563
126. CA Fulcher S de Graaf Mahoney TS Zimmerman 1987 FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting Blood 69 1475 1480 2436689
127. CR Hay W Ollier L Pepper A Cumming S Keeney AC Goodeve BT Colvin FG Hill FE Preston IR Peake 1997 HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party Thromb Haemost 77 234 237 9157572
128. KW Wucherpfennig PM Allen F Celada IR Cohen R De Boer KC Garcia B Goldstein R Greenspan D Hafler P Hodgkin ES Huseby DC Krakauer D Nemazee AS Perelson C Pinilla RK Strong EE Sercarz 2007 Polyspecificity of T cell and B cell receptor recognition Semin Immunol 19 216 224 17398114
129. AK Abbas KM Murphy A Sher 1996 Functional diversity of helper T lymphocytes Nature 383 787 793 8893001
130. SL Reiner 2007 Development in motion: helper T cells at work Cell 129 33 36 17418783
131. LE Harrington RD Hatton PR Mangan H Turner TL Murphy KM Murphy CT Weaver 2005 Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages Nat Immunol 6 1123 1132 16200070
132. H Park Z Li XO Yang SH Chang R Nurieva YH Wang Y Wang L Hood Z Zhu Q Tian C Dong 2005 A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 Nat Immunol 6 1133 1141 16200068
133. C Dong 2008 TH17 cells in development: an updated view of their molecular identity and genetic programming Nat Rev Immunol 8 337 348 18408735
134. T Korn M Oukka V Kuchroo E Bettelli 2007 Th17 cells: effector T cells with inflammatory properties Semin Immunol 19 362 371 18035554
135. D Jin L Zhang J Zheng Y Zhao 2008 The inflammatory Th 17 subset in immunity against self and non-self antigens Autoimmunity 41 154 162 18324485
136. J Qian M Borovok L Bi HH Kazazian Jr. LW Hoyer 1999 Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A Thromb Haemost 81 240 244 10063999
137. MT Reding S Lei H Lei D Green J Gill BM Conti-Fine 2002 Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients Thromb Haemost 88 568 575 12362225
138. N Burdin C Van Kooten L Galibert JS Abrams J Wijdenes J Banchereau F Rousset 1995 Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes J Immunol 154 2533 2544 7533177
139. SL Constant K Bottomly 1997 Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches Annu Rev Immunol 15 297 322 9143690
140. F Malisan F Briere JM Bridon N Harindranath FC Mills EE Max J Banchereau H Martinez-Valdez 1996 Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes J Exp Med 183 937 947 8642297
141. V Kindler RH Zubler 1997 Memory, but not naive, peripheral blood B lymphocytes differentiate into Ig-secreting cells after CD40 ligation and costimulation with IL-4 and the differentiation factors IL-2, IL-10, and IL-3 J Immunol 159 2085 2090 9278293
142. A Kelso 1995 Th1 and Th2 subsets: paradigms lost Immunol Today 16 374 379 7546192
143. G Hu D Guo NS Key BM Conti-Fine 2007 Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients Thromb Haemost 97 788 794 17479189
144. DJ Lenschow TL Walunas JA Bluestone 1996 CD28/B7 system of T cell costimulation Annu Rev Immunol 14 233 258 8717514
145. EA Tivol F Borriello AN Schweitzer WP Lynch JA Bluestone AH Sharpe 1995 Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 Immunity 3 541 547 7584144
146. P Waterhouse JM Penninger E Timms A Wakeham A Shahinian KP Lee CB Thompson H Griesser TW Mak 1995 Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 Science 270 985 988 7481803
147. W Li XX Zheng CS Kuhr JD Perkins 2005 CTLA4 engagement is required for induction of murine liver transplant spontaneous tolerance Am J Transplant 5 978 986 15816877
148. BR Blazar PA Taylor PS Linsley DA Vallera 1994 In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice Blood 83 3815 3825 7515723
149. J Qian M Collins AH Sharpe LW Hoyer 2000 Prevention and treatment of factor VIII inhibitors in murine hemophilia A Blood 95 1324 1329 10666206
150. G Rossi J Sarkar D Scandella 2001 Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A Blood 97 2750 2757 11313267
151. BM Reipert M Sasgary RU Ahmad W Auer PL Turecek HP Schwarz 2001 Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance Thromb Haemost 86 1345 1352 11776297
152. CH Miao P Ye AR Thompson DJ Rawlings HD Ochs 2006 Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice Blood 108 19 27 16507778
153. BM Ewenstein WK Hoots JM Lusher D DiMichele GC White 2nd B Adelman K Nadeau 2000 Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors Haematologica 85 35 39 11187868
154. C Hausl RU Ahmad HP Schwarz EM Muchitsch PL Turecek F Dorner BM Reipert 2004 Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders Blood 104 115 122 15001466
155. B Peng P Ye BR Blazar GJ Freeman DJ Rawlings HD Ochs CH Miao 2008 Transient blockade of the inducible costimulator pathway generates long-term tolerance for factor VIII following nonviral gene transfer into hemophilia A mice Blood 112 5 1662 1672 18574023
156. AG Brox H Laryea M Pelletier 1998 Successful treatment of acquired factor VIII inhibitors with cyclosporin Am J Hematol 57 87 88 9423825
157. A Wiestner HJ Cho AS Asch MA Michelis JA Zeller EI Peerschke BB Weksler GP Schechter 2002 Rituximab in the treatment of acquired factor VIII inhibitors Blood 100 3426 3428 12384448
158. R Stasi M Brunetti E Stipa S Amadori 2004 Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia Blood 103 4424 4428 14996701
159. NI Rodriguez WK Hoots 2008 Advances in hemophilia: experimental aspects and therapy Pediatr Clin North Am 55 357 376 18381091
160. E Berntorp J Astermark E Carlborg 2000 Immune tolerance induction and the treatment of hemophilia. Malmo protocol update Haematologica 85 48 50 11187871
161. E Carlborg J Astermark S Lethagen R Ljung E Berntorp 2000 The Malmo model for immune tolerance induction: impact of previous treatment on outcome Haemophilia 6 639 642 11122389
162. E Berntorp A Shapiro J Astermark VS Blanchette PW Collins D Dimichele C Escuriola CR Hay WK Hoots CA Leissinger C Negrier J Oldenburg K Peerlinck MT Reding C Hart 2006 Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference Haemophilia 12 Suppl 6 1 7 17123387
163. GL Hu DK Okita BM Conti-Fine 2004 T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects J Thromb Haemost 2 1908 1917 15550021
164. GL Hu DK Okita BM Diethelm-Okita BM Conti-Fine 2003 Recognition of coagulation factor VIII by CD4+ T cells of healthy humans J Thromb Haemost 1 2159 2166 14521599
165. MT Reding H Wu M Krampf DK Okita BM Diethelm-Okita BA Christie NS Key BM Conti-Fine 2000 Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects Thromb Haemost 84 643 652 11057864
166. MT Reding DK Okita BM Diethelm-Okita TA Anderson BM Conti-Fine 2004 Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII J Thromb Haemost 2 1385 1394 15304045
167. MT Reding DK Okita BM Diethelm-Okita TA Anderson BM Conti-Fine 2003 Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII J Thromb Haemost 1 1777 1784 12911593
168. LW Hoyer J Qian 2000 Characterization of the immune response to factor VIII using hemophilia A mice Haematologica 85 100 102 11187859
169. H Wu M Reding J Qian DK Okita E Parker P Lollar LW Hoyer BM Conti-Fine 2001 Mechanism of the immune response to human factor VIII in murine hemophilia A Thromb Haemost 85 125 133 11204564
170. TD Jones WJ Phillips BJ Smith CA Bamford PD Nayee TP Baglin JS Gaston MP Baker 2005 Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII J Thromb Haemost 3 991 1000 15869596
171. EJ Novak AW Liu GT Nepom WW Kwok 1999 MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen J Clin Invest 104 R63 R67 10606632
172. JM Saint-Remy S Lacroix-Desmazes J Oldenburg 2004 Inhibitors in haemophilia: pathophysiology Haemophilia 10 Suppl 4 146 151 15479388
173. BM Reipert PM van den Helden HP Schwarz C Hausl 2007 Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors Br J Haematol 136 12 25 17222196
174. S Sakaguchi T Yamaguchi T Nomura M Ono 2008 Regulatory T cells and immune tolerance Cell 133 775 787 18510923
175. C Kamate PJ Lenting HM van den Berg T Mutis 2007 Depletion of CD4+/CD25high regulatory T cells may enhance or uncover factor VIII-specific T-cell responses in healthy individuals J Thromb Haemost 5 611 613 17155960
176. Ettinger RA, James EA, Thompson AR, Kwok WW, Pratt KP (2008) HLA-DE-restricted T-cell responses to Factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P. Haemophilia, in press
177. James EA, van Haren SD, Ettinger RA, Thompson AR, Kwok WW, Voorberg J, Pratt KP (2008) HLA-DRB11101- restricted T cells from two unrelated mild hemophilia A inhibitor subjects with missence genotype R593C respond to the same minimal epitope. Blood 112 (Ash Annual Meeting Abstract 1212): 441-442